Free tool
FAERS Monitor: Lupkynis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213716 or its brand name (Lupkynis, Voclosporin). Reports on generic versions are filed under their own applications.
Reports
9,788
Serious
1,987
20% of reports
Hospitalization
849
Death reported
61
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- therapy interrupted991
- product dose omission issue870
- hypertension807
- headache764
- nausea715
- fatigue625
- diarrhoea605
- proteinuria557
- blood pressure increased440
- product use issue427
- glomerular filtration rate decreased380
- vomiting369
- abdominal discomfort356
- arthralgia337
- dizziness311
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 431 |
| 2022 | 1,006 |
| 2023 | 1,506 |
| 2024 | 2,002 |
| 2025 | 2,316 |
| 2026 | 2,526 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,371 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| glomerular filtration rate decreasedSignal | 380 | 68.5 | 62.0 | 24,461 |
| proteinuriaSignal | 557 | 64.8 | 59.7 | 33,939 |
| therapy interruptedSignal | 991 | 30.2 | 28.5 | 27,659 |
| hypertensionSignal | 807 | 8.2 | 7.7 | 5,139 |
| product dose omission issueSignal | 870 | 6.4 | 6.0 | 3,980 |
| blood pressure increasedSignal | 440 | 6.2 | 5.7 | 1,922 |
| product use issueSignal | 427 | 4.9 | 4.5 | 1,327 |
| abdominal discomfortSignal | 356 | 4.6 | 4.1 | 994 |
| headacheSignal | 764 | 2.6 | 2.4 | 787 |
| diarrhoeaSignal | 605 | 2.0 | 1.9 | 318 |
| nausea | 715 | 1.9 | 1.8 | 338 |
| arthralgia | 337 | 1.7 | 1.6 | 108 |
| fatigue | 625 | 1.7 | 1.6 | 197 |
| vomiting | 369 | 1.7 | 1.5 | 105 |
| dizziness | 311 | 1.3 | 1.2 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.